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Abstract
Genetic alterations enhancing cell survival and suppressing apoptosis are hallmarks of cancer that significantly reduce the
efficacy of chemotherapy or radiotherapy. The Inhibitor of Apoptosis Protein (IAP) family hosts conserved proteins in the
apoptotic pathway whose over-expression, frequently found in tumours, potentiates survival and resistance to anticancer
agents. In humans, IAPs comprise eight members hosting one or more structural Baculoviral IAP Repeat (BIR) domains.
Cellular IAPs (cIAP1 and 2) indirectly inhibit caspase-8 activation, and regulate both the canonical and the non-canonical NF-
kB signaling pathways. In contrast to cIAPs, XIAP (X chromosome-linked Inhibitor of Apoptosis Protein) inhibits directly the
effector caspases-3 and -7 through its BIR2 domain, and initiator caspase-9 through its BIR3 domain; molecular docking
studies suggested that Smac/DIABLO antagonizes XIAP by simultaneously targeting both BIR2 and BIR3 domains. Here we
report analytical gel filtration, crystallographic and SAXS experiments on cIAP1-BIR3, XIAP-BIR3 and XIAP-BIR2BIR3 domains,
alone and in the presence of compound 9a, a divalent homodimeric Smac mimetic. 9a is shown to bind two BIR domains
inter- (in the case of two BIR3) and intra-molecularly (in the case of XIAP-BIR2BIR3), with higher affinity for cIAP1-BIR3,
relative to XIAP-BIR3. Despite the different crystal lattice packing, 9a maintains a right handed helical conformation in both
cIAP1-BIR3 and XIAP-BIR3 crystals, that is likely conserved in solution as shown by SAXS data. Our structural results
demonstrate that the 9a linker length, its conformational degrees of freedom and its hydrophobicity, warrant an overall
compact structure with optimal solvent exposure of its two active moieties for IAPs binding. Our results show that 9a is a
good candidate for pre-clinical and clinical studies, worth of further investigations in the field of cancer therapy.
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Introduction
Apoptosis is a process of programmed cell death essential for
homeostasis maintenance in multicellular organisms, which is
regulated by a subset of caspases (Cysteine-dependent ASPartyl-
specific proteASES) in charge of propagating, once activated, the
apoptotic signal to the nucleus [1]. The suppression of caspase
activity occurs in the presence of specific members of the IAP
(Inhibitor of Apoptosis Proteins) family [2,3]. In particular, cIAP1
and cIAP2 (cellular IAPs) are indirect inhibitors of caspases
activity, whereas XIAP (X chromosome-linked Inhibitor of
Apoptosis Protein) is able to directly inhibit both initiator and
effector caspases. All IAPs host one to three BIR (Baculoviral IAP
Repeat) domains that are critical for their anti-apoptotic activity.
In particular, it has been shown that the XIAP-BIR2 domain is
responsible for the inhibition of effector caspases, whereas XIAP-
BIR3 directly binds to and inhibits initiator caspase-9, which can
also be recognized by cIAP1-BIR3 [4]. The caspase inhibitory
activity of XIAP is endogenously antagonized by Smac/DIABLO
(Second mitochondria-derived activator of caspases/Direct IAp
Binding protein with Low pI), which is released from mitochon-
dria together with cytochrome c in response to death stimuli. The
N-terminal tetrapeptides of Smac/DIABLO and caspases (known
as Iap Binding Motives, IBMs) competitively bind to the same
XIAP active pocket (the IBM binding cleft), resulting in activation
or inhibition of apoptosis, respectively. Since the structural details
of IBM interactions with XIAP and cIAPs have been previously
described [4,5], the IBM peptides provide a natural basis for the
design of Smac-mimetics. These compounds have been shown to
displace caspases 3, 7 and 9 from XIAP-BIR2 and –BIR3
inhibitory pockets, and to induce auto-ubiquitination and degra-
dation of cIAPs by perturbing BIR3/RING domain interaction
[6,7]. Therefore, the Smac-mimetics can restore the apoptotic
cascade operating in a variety of signaling pathways.
Over the last few years several Smac-mimetics have been
designed (based on the Smac/DIABLO N-terminal tetrapeptide
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AVPI), with the aim of exploiting their pro-apoptotic properties,
alone or in combination with other pro-apoptotic compounds such
as TRAIL [8]; these initiatives led to the progressive development
of new and potent compounds, some of which are currently in
phase I clinical trials [9]. One of the most promising Smac-
mimetics is SM164, a divalent molecule composed of two moieties,
connected by a flexible linker, aimed to target simultaneously two
BIR domains [10].
Taking advantage of the experience gathered with monovalent
Smac-mimetics design [11,12], we generated a library of twenty
divalent compounds, belonging to three structural sub-classes,
each characterized by distinct linkers or central scaffold-substitu-
tions, to explore different molecular rigidity patterns and to test
related metabolic assumptions [13,14]. All divalent compounds
were fully profiled in vitro, and compared in terms of overall drug-
like properties. In particular, 9a (Fig. 1) displayed in vitro low nM
affinity values for the BIR3 domains of XIAP, cIAP1 and cIAP2,
but also for XIAP-BIR2BIR3; it also showed good cytotoxicity
properties against a selected breast cancer cell line. Notably, due to
its ionisable secondary amino groups, 9a is soluble in physiological
buffer and could be administered in vivo; thus, it resulted as the
most promising compound in our library, and was selected for
early in vivo characterization [13,14]. 9a displayed significant
potency as a single agent in reducing the development of solid
tumours in mice injected subcutaneously with a human ovarian
cancer cell line, and increased the median survival time of mice in
a human ovarian ascites model [14].
In this communication we present biochemical, biophysical and
structural characterization of 9a in its complexes with XIAP-BIR3,
XIAP-BIR2BIR3 and cIAP1-BIR3. In particular, we report data
on compound 9a binding to different BIR domains through
analytical gel filtration and small angle X-ray scattering (SAXS).
Moreover, we present the crystal structures of cIAP1-BIR3 and
XIAP-BIR3 domains in the presence of 9a, describing the
molecular details of divalent Smac-mimetic recognition. Taken
together, all the experimental evidences here reported suggest that
9a is one of the most powerful divalent Smac-mimetics known to
date; the structural analysis of its recognition patterns, here
presented, is the basis for further optimization in terms of target
affinity and bioavailability.
Results
Cellular Cytotoxicity
Preliminary cytotoxicity tests of 9a after 72 hours of treatment
versus MDA-MB-231 (a breast cancer cell line that has repeatedly
been used to test Smac-mimetics/XIAP inhibitors), HL60 (known
to be Smac-mimetic sensitive), and PC-3 cells (as an example of
Smac-mimetic refractory cells), were addressed [14]. 9a showed
nanomolar cytotoxicity both in MDA-MB-231 and HL60 cell
lines, whereas it was inactive against the PC-3 cell line, as
expected. The relative IC50 values observed are shown in Table 1.
Caspase Activation and cIAP Degradation
To test the capability of inducing caspase activation and
apoptosis, MDA-MB-231 cells were treated with 9a, or left
untreated. 9a not only inhibited cell growth in the MDA-MB-231
cell line, but Western blot analysis showed activation of caspase-8,
-3 and -9, and apoptosis (Fig. 2). Moreover, Western blot analysis
shows that 9a induces degradation of cIAP1 and of cIAP2 (Fig. 2),
already at 30 min post treatment.
Fluorescence Polarization Assays
Binding and displacement assays based on fluorescent polari-
zation were used to evaluate the affinities of 9a for human cIAP1-,
cIAP2-, XIAP-BIR3 and XIAP-BIR2BIR3 domains. Saturation
binding experiments were performed to determine the binding
affinity of the fluorescent probes to the IAP constructs of interest,
Figure 1. Chemical structure of tail-tail dimer 9a. The left inset shows a framed structure of the divalent Smac-mimetics based on the 1-aza-2-
oxobicyclo[5.3.0]decane scaffold.
doi:10.1371/journal.pone.0049527.g001
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as previously reported [11,15,16]. Competitive binding assays
revealed that 9a displayed low nanomolar IC50 values for all tested
IAP constructs (Table 1).
Analytical Gel Filtration
In order to check whether simultaneous interactions of the
divalent inhibitor with two cIAP1-BIR3 or XIAP-BIR3 domains
could take place in solution, we performed analytical gel filtration
assays mixing the different protein domains (33 mM) with a large
excess of 9a (1 mM). The chromatograms obtained for XIAP-
BIR3 in the presence of 9a exhibited a shift of 1 mL in elution
volume (Ve = 10.7 mL) relative to the untreated protein
(Ve = 11.7 mL), revealing domain dimerization upon ligand
binding (Fig. 3A). In order to exclude that the dimerization of
XIAP-BIR3 could be due to the formation of an intermolecular
disulfide bridge involving residue Cys351 (induced by the presence
of 9a), we performed an analytical gel filtration on the XIAP-BIR3
Cys351Ser mutant, in the absence/presence of the divalent
compound, obtaining the same results reported for the wild type
protein (Ve = 11.7/10.7 mL, respectively). In contrast, the chro-
matogram of XIAP-BIR2BIR3 exhibited a slight peak shift
(0.3 mL) toward a higher elution volume in the presence of 9a,
indicating a more compact conformation of the protein (Fig. 3B).
The simultaneous binding of the two heads of divalent 9a to BIR2
and BIR3 domains, resulting in a decrease of their mutual
distance, may explain the observed Ve shift (see also the SAXS
data below). As expected, analytical gel filtration performed in the
presence of a monovalent moiety of 9a did not show any peak shift
relative to the apo-proteins.
Surprisingly, analytical gel filtration assays performed on cIAP1-
BIR3 did not show any peak shift in the presence of an excess of
9a. To shed light on such behavior, we performed new gel
filtration experiments mixing equimolar amounts (33 mM) of the
proteins (XIAP- or cIAP1-BIR3) and of 9a. The resulting
chromatograms showed for XIAP-BIR3/9a the same peak shift
observed in the presence of an excess of inhibitor, and a peak shift
of about 1.3 mL for cIAP1-BIR3/9a (from Ve = 12.9 mL to
Ve = 11.6 mL, Fig. 3C).
Such apparently contradictory results can be explained taking
into account the different affinities of the cIAP1- and XIAP-BIR3
domains for 9a in two different states: 1) when the ligand is free in
solution; 2) when the ligand is already bound to one BIR3 domain,
as summarized by the dissociation constants K1 and K2:
Bzau
K1
BazBu
K2
BaB; K1~
B½  a½ 
Ba½  ; K2~
B½  Ba½ 
BaB½ 
B = BIR3, a = 9a
In fact, after mixing together the protein and a large excess of the
inhibitor, an expected behavior (K1,K2) will be the saturation of
all the available BIR3 domains by one head of 9a, hampering the
formation of dimers (no variations in Ve), as observed for cIAP1-
BIR3. On the contrary if BIR3 has a considerably higher affinity
for the BIR3/9a complex (K1..K2), the equilibrium would be
Table 1. Cytotoxic activity displayed by 9a on MDA-MB-231, HL60 and PC-3 cell lines, determined in three independent
experiments (each done in triplicate).
Cytotoxicity IC50 [nM] Fluorescence Binding Assays IC50 [nM]
MDA-MB-231 HL60 PC-3 XIAP-BIR3 XIAP-BIR2BIR3 cIAP1-BIR3 cIAP2-BIR3
5561.0 7165.0 .50.000 25.460.1 0.860.1 5.460.1 1.960.9
In vitro IC50 values for 9a in complex with XIAP-BIR3, XIAP-BIR2BIR3, cIAP1-BIR3, cIAP2-BIR3 determined by 3 independent experiments.
doi:10.1371/journal.pone.0049527.t001
Figure 2. Western blot of MDA-MB-231 cells untreated or
treated with 9a. Upper part: cIAP1 and cIAP2 degradation in the
MDA-MB-231 cell line after 30 min and 6h of treatment with 9a.
Proteins were revealed by Western blot using polyclonal antibodies
specific for cIAP1 and cIAP2. Lower part: activation of caspase-8 (arrows
indicate p55, p43/41 and p18 forms), -9 (p37) and -3 (p17 and p19) by
9a (p89). Proteins were revealed by Western blot using rabbit polyclonal
antibodies specific for cleaved Parp, and cleaved caspase-8, -9 and -3.
Prestained Protein SHARPMASS V (112250 kDa; EuroClone) was used as
molecular weight marker.
doi:10.1371/journal.pone.0049527.g002
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shifted toward dimer (BaB) formation, as observed for XIAP-BIR3
(variation in Ve). On the other hand, when the amount of
inhibitor is comparable with that of the protein, there will be an
equilibrium between the monomeric and dimeric adducts even if
K1,K2 (Fig. 3C). As a whole, the analytical gel filtration results
indicate that 9a is able to bind simultaneously two BIR domains
(either BIR2 or BIR3), and bring them to a relatively compact
(dimeric for XIAP-BIR3 and cIAP1-BIR3) structure.
Crystal Structures of XIAP- and cIAP1-BIR3 Bound to 9a
Overall structure. The binding of 9a to the BIR3 domains
of XIAP and cIAPs was investigated through X-ray crystallogra-
phy. The 3D structures of cIAP1- and XIAP-BIR3 complexes with
the ligand were solved through the molecular replacement
method, using search models based on the BIR3 structure of
cIAP1 (pdb: 3MUP [15]) and of XIAP (pdb: 3CLX [11]) and
refined at 2.6 A˚ and 3.3 A˚ resolution, respectively (Table 2).
In the cIAP1-BIR3 structure, the crystal displays four BIR3
domains and two molecules of 9a in the asymmetric unit, forming
a ring-like assembly composed of two dimers (AC and BD; Fig. 4A
shows the AC dimer). The crystal packing is the same observed for
the structure of cIAP1-BIR3 bound to a monovalent Smac-
mimetic (pdb: 3MUP; [15]), suggesting that such intermolecular
arrangement is independent of the presence of the divalent
compound. The four independent BIR3 domains display very
similar structures, showing r.m.s.d. values in the 0.29 – 0.46 A˚
range (calculated over 101 Ca pairs).
In the XIAP-BIR3 structure, ten molecules in the asymmetric
unit are assembled into five dimers (AF, BG, CJ, DK, EL), each
arranged around a local twofold axis, in head-to-tail fashion,
stabilized by the bound divalent 9a (Fig. 4B, AF dimer).
The divalent Smac-mimetic heads bind to both cIAP1-BIR3
and XIAP-BIR3 in the conserved IBM cleft, between the b3
strand and the a3 helix, roughly lined by residues Gly306, Arg/
Thr308, Cys/Asp309, Glu/Lys311, Asp/Glu314, Glu/Gln319
and Trp323, in cIAP1/XIAP-BIR3, respectively (Fig. 5A, left and
right panels). In both structures the two heads of the ligand adopt
antiparallel orientations, with distances of 17.0 and 11.8 A˚
between the N1 atoms of their triazole rings, for cIAP1- and
XIAP-BIR3, respectively (Fig. 4A and B). In both cases the overall
structure adopted by 9a is a sort of right-handed helix with
different pitches due mainly to the rotation of ,180u of the
respective triazole rings (Fig. 4A and B).
The inhibitor linker region. The segment linking the two
inhibitory heads of 9a (starting from the triazole ring) provides few
hydrophobic contacts to the protein that do not seem to influence
the recognition of the BIR3 IBM pocket by the Smac-mimetic. In
the case of XIAP-BIR3, the 9a central phenyl ring, orthogonal to
the dimer twofold axis (Fig. 4B), is hosted in a cleft between two
BIR3 molecules surrounded by the N-terminal residues Asn249
and Pro251, and by the aromatic residues Trp323 and Tyr324.
The interaction of 9a with XIAP-BIR3 N-terminal region
promotes order in the N-terminal amino acids (248–253) that
could be modelled in the electron density. In cIAP1 the linker
Figure 3. Analytical Gel Filtration Chromatograms. A) XIAP-BIR3 (33 mM) in absence/presence of an excess (1 mM) of 9a. B) XIAP-BIR2BIR3 in
absence/presence of an excess (1 mM) of 9a. C) cIAP-BIR3 in absence/presence of an equal amount (33 mM) of 9a.F
doi:10.1371/journal.pone.0049527.g003
Table 2. X-ray data-collection and refinement statistics for the cIAP-BIR3/9a and XIAP-BIR3/9a complexes.
cIAP-BIR3/9a XIAP-BIR3/9a
Space group C2 P212121
Unit-cell parameters (A˚) a = 79.1, b = 81.3, c = 96.9; b= 95.7u a = 65.4, b = 130.5, c = 215.7
Nu of molecules per a.u. 4 10
Resolution (A˚) 56.6–2.6 54.0–3.3
Mosaicity (u) 0.8 0.5
Nu of unique reflections 18,610 (2,731) 28,624 (4,112)
Completeness (%) 98.5 (99.5) 99.9 (100.0)
Redundancy 2.7 (2.7) 3.5 (3.6)
Rmerge { (%) 13.4 (58.5) 25.8 (50.8)
Average I/s (I) 5.1 (1.6) 5.0 (2.6)
R factor { (%) 25.7 21.0
Rfree 1 (%) 32.2 27.6
r.m.s. bond lengths (A˚) 0.009 0.009
r.m.s. bond angles (u) 1.19 1.28
Average protein B factor (A˚2) 52.8 56.3
Average Smac-mimetic B factor (A˚2) 57.4 46.0
Residues in most favoured regions (%) 87,9% 85,2%
Residues in additionally allowed regions (%) 10,9% 14,8%
PDB-ID 4EB9 4EC4
Values in parentheses are for the highest resolution shell.
{Rmerge =S |I - (I)|/SI6 100, where I is intensity of a reflection and (I) is its average intensity.
{R factor =S |Fo - Fc|/S |Fo| 6 100.
1Rfreeis calculated on 5% randomly selected reflections, for cross-validation.
doi:10.1371/journal.pone.0049527.t002
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Figure 4. Dimeric assemblies of cIAP1- and XIAP1-BIR3 bound to 9a. A) X-Ray structure of cIAP1-BIR3 dimer (cartoon in blue and pale blue)
in complex with 9a (green sticks). B) X-Ray structure of XIAP-BIR3 dimer in complex with 9a: the A and F molecules are in orange and pale yellow,
respectively, 9a is represented as green sticks (drawn with Pymol).
doi:10.1371/journal.pone.0049527.g004
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Figure 5. cIAP1- and XIAP1-BIR3 bound to one head of 9a. A) Left panel, XIAP-BIR3 (orange cartoon) with 9a (green sticks). The main residues
involved in ligand interaction are shown in orange sticks; right-panel, cIAP-BIR3 (blue cartoon) with 9a (green sticks) and the main residues involved
in ligand interaction (blue sticks). B) Left and right panels as A) with protein surface coloured by electrostatic potential (calculated using APBS2; drawn
with Pymol).
doi:10.1371/journal.pone.0049527.g005
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segment is in contact with a hydrophobic surface built by the C-
terminal a-helices of two BIR3 domains, in particular by residues
Leu354 and Leu355.
SAXS Analysis of XIAP-BIR2BIR3 with/without 9a
The two scattering patterns of XIAP-BIR2BIR3 in solution, in
the absence/presence of 9a, are shown in Fig. 6A. They result
from the combination of data recorded using an on-line HPLC
apparatus to ensure protein monodispersity (small-angle data),
with data from a higher concentration sample (wide-angle), as
explained in Experimental Procedures. Inhibitor binding causes
global conformational changes in the protein, as indicated by
significant differences between the two curves (Fig. 6A). Guinier
plot analysis shows a reduction of the radius of gyration in the
presence of the inhibitor from 25.0 to 20.7 (60.2) A˚, with a
molecular mass estimate, derived from I(0)/c values, increasing
from 28 to 29 kDa in the presence of 9a (Mw 1.4 kDa).
Accordingly, in the distance distribution functions p(r) the
maximal diameter Dmax and radius of gyration Rg values undergo
marked reductions, from 92 to 63 (65) A˚, and from 25.7 to 20.7
(60.2) A˚, upon inhibitor binding, respectively (Fig. 6B). All these
results point toward a major conformational transition of XIAP-
BIR2BIR3 from an extended (Fig. 6B inset, blue volume) to a
more compact conformation (Fig. 6B inset, red volume) upon
inhibitor binding, as already observed for a different divalent
compound [16]. The p(r) profile of the apo protein is broadly
spread with a first peak around 20 A˚ and a clear shoulder between
35 and 50 A˚, corresponding predominantly to intra and
interdomain distances, respectively (Fig. 6B, blue curve), while
most distances are found in a narrow 10–45 A˚ range in the
presence of the inhibitor with a much shorter Dmax (Fig. 6B, red
curve). This suggests that the two BIR2 and BIR3 structured
domains are well separated in the absence of 9a, likely to be
mobile around a flexible linker, while the divalent Smac-mimetic
brings them into close proximity, resulting in the narrower
distance distribution observed.
XIAP-BIR2BIR3 ab initio modeling. The shape of XIAP-
BIR2BIR3 in the absence/presence of the inhibitor was investi-
gated ab initio using the program Dammif [17]. We produced ten
low-resolution models with/without 9a, all in excellent agreement
with experimental data. Models superposition yielded values of ca.
0.85/0.75 of the normalized spatial discrepancy (NSD) for the
protein in the absence/presence of the inhibitor, respectively,
showing that all shapes in a series were very similar. The shape of
XIAP-BIR2BIR3 in the absence of the divalent Smac-mimetic
appears elongated and rather slim, large enough to accommodate
the two BIR domains in non-contiguous positions together with
the linker segment (Fig. 6B inset, blue volume). In contrast, the
inhibitor-bound XIAP-BIR2BIR3 shows a broader, more com-
pact shape that can accommodate the two domains in close
proximity (Fig. 6B inset, red volume).
Apo XIAP-BIR2BIR3 modeling using crystal
structures. Starting from a random mutual position of the
two domains, the free XIAP-BIR2BIR3 construct was refined with
respect to the SAXS data using the program Bunch [18], that
modifies the relative position and orientation of the two domains
while describing the missing parts (N- and C-terminal stretches
together with the central linker) as chains of dummy residues (see
Experimental Procedures section for details). Several models were
obtained, nicely fitting the experimental data (x= 0.9). After
superimposition of the BIR2 domain from the various models, thus
fixing the location of BIR2, the BIR3 domains and linkers appear
to be widely distributed, with r.m.s.d. values over the BIR3 Ca
atoms ranging between 11 and 56 A˚ (Fig. S1). Therefore, it
appears that there is not a unique solution and that many different
XIAP-BIR2BIR3 conformations can account for our data. All
conformations exhibit domains at a moderate distance (13 A˚ to 19
A˚ between closest Ca atoms), suggesting that the molecule does
not adopt a unique, well-defined structure but a manifold of
conformations (Fig. S1). Indeed, the two domains are linked by a
segment of 29 residues that is predicted to be extensively
disordered and that likely provides substantial degrees of freedom
for their mutual location. Accordingly, we submitted our data to
analysis using the Ensemble Optimized Method (EOM) [19] that
describes the sample as an ensemble of randomly created
conformations (see Experimental Procedures). Panels C and D in
Figure 6 show the distribution of values of Rg and Dmax of the
optimized ensembles compared to that of the starting pool. Both
distributions show a major shift towards smaller values, indicating
that XIAP-BIR2BIR3 adopts compact, less extended conforma-
tions more frequently than expected if the linker were oriented
completely randomly. Such results suggest that XIAP-BIR2 and -
BIR3 do not actually behave as independent domains, but are,
most of the time, involved in some form of interaction even in the
absence of 9a.
Modeling of complex XIAP-BIR2BIR3/9a using crystal
structures. Starting from the crystal structure of the XIAP-
BIR3 homo-dimer bound to 9a, we superimposed a BIR2 domain
on one BIR3 domain thus producing an initial model of the
interaction between the two domains in the presence of the ligand.
We then used the program Bunch to model the missing parts
according to the SAXS data, but no acceptable fit could be
obtained. As a result, we undertook a new modeling stage using
program Coral [20] in which domains BIR2 and BIR3 (each one
bound to one half of 9a) were free to move under a 5 A˚ distance
restraint between the two carbon atoms on each side of the broken
methylbenzene bond in 9a. This made molecular sense in view of
the numerous single bonds in the inhibitor offering as many
possible rotations. Several models were obtained with a much-
improved fit to the data (Fig. 7A with a x-value of 1.3). However,
the degrees of freedom of 9a make it likely that the XIAP-
BIR2BIR3/9a complex exhibits a certain level of restricted
mobility, so that the reported model (Fig. 7B) should be considered
only as a representative of the ensemble of conformations explored
by the molecule.
Discussion
Compound 9a is a tail-tail homodimeric divalent Smac-mimetic
that was rationally designed, together with nineteen other divalent
compounds (tail-tail, head-head or head-tail, Fig. 1), to study how
bifunctional inhibitors can bind and distinguish between XIAP-
and cIAPs-BIR2BIR3 domains. Among these, 9a showed prom-
inent binding activity to BIR3 domains of XIAP and cIAPs, and to
XIAP-BIR2BIR3 (Table 1), low cytotoxicity in two different cell
lines (MDA-MB-231 and HL60, Table 1), and the capability to
induce activation of caspases and apoptosis (Fig. 2). Moreover, the
divalent compound proved effective (alone) in in vivo treatments,
after intraperitoneal daily administration, in two human IGROV-
1 ovarian cancer models, showing reduction of subcutaneous
tumor growth in nude mice, and increase of the median survival
time of mice in ascites model [14].
Inspection of the crystal structures suggests that the higher
affinity of 9a for cIAP1-BIR3, relative to XIAP-BIR3 (Table 1), is
the result of: i) a larger IBM cleft, accommodating the ligand, due
to Val/Leu292 and Asp/Glu314 residue substitutions in cIAP1/
XIAP, respectively; ii) the presence of p-cation interactions
stabilizing the ligand phenyl ring, due to Arg/Thr308 substitution
IAP Family Recognition by Divalent Smac-Mimetic
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(cIAP1/XIAP); and, iii) the increased negative charge located
close to the ligand N-terminal end, due to Glu/Lys311 and Glu/
Gln319 substitutions (cIAP1/XIAP) (Fig. 5A, B). Such features,
promoting 9a affinity for cIAP1-BIR3, are partially compensated
by the presence of Cys309 in cIAP1-BIR3, in place of Asp309,
which in XIAP-BIR3 establishes an additional hydrogen bond
with the ligand hydroxyl group located in the 4th-position of the
azabicyclo[5.3.0]alkane scaffold.
Binding of the divalent compound to XIAP-BIR3 results in a
crystal packing that differs from that observed in the crystal
structures of the XIAP-BIR3 complexes with monovalent Smac-
mimetic compounds known to date [11,12,16,21,22]. Notably, the
crystal lattice packing is also different from that observed for
XIAP-BIR3 in complex with the divalent compound-3 [16] (PDB:
3G76), whose crystal asymmetric unit hosts eight BIR3 molecules
and eight compound-3 molecules, each of which has one
inhibitory head bound to BIR3 and the other devoid of any
contact to the protein. In contrast, 9a induces the formation of
BIR3 dimers, in head-to-tail fashion, with a buried surface of
about 652 A˚2. Such dimers, not considering the 9a contributions,
are stabilized by salt bridges and H-bonds mainly involving N-
terminal residues Ser246, Asp247, Arg248, Ser253, and Arg258,
and C-terminal residues His346, Ser347, Glu349, and Glu350
(analysis performed using the program ‘PISA’ [23]).
In the case of the cIAP1-BIR3/9a complex, the crystal packing
matches that observed for cIAP1-BIR3 in the presence of the
monovalent compound Smac037 [15]; thus, in this case, 9a
(although conserving its overall right-handed helical conformation)
apparently adapts its flexibility to a preferred crystallographic
packing [15]. Such different behaviors observed for crystal packing
are in keeping with the XIAP-BIR3 higher affinity for 9a
complexed with one BIR3 domain, relative to that for the free
inhibitor, as shown by gel filtration experiments. In fact, the higher
affinity of XIAP-BIR3 for the bound ligand can be explained by
the cooperation of two distinct contact interfaces, namely BIR3-
BIR3 and BIR3-9a free head. Such hypothesis is supported by the
existence of a larger interaction surface area for the XIAP-BIR3
dimer compared to cIAP1-BIR3, as assessed by the ’PISA’
program [23] (association interface areas of 652/459 A˚2, and DGs
of 26.9/25.4 kcal/mol for XIAP/cIAP1-BIR3, respectively).
Figure 6. SAXS study of XIAP-BIR2BIR3. A) experimental scattering patterns with associated error bars; blue line: free XIAP-BIR2BIR3; red line:
XIAP-BIR2BIR3 complexed with 9a. B) distance distribution functions p(r); color code as in panel A. C) distribution of Rg values of free XIAP-BIR2BIR3;
green: random pool; orange: selected ensembles fitting the data; D) distribution of Dmax values; color code as in panel C.
doi:10.1371/journal.pone.0049527.g006
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Accordingly, the remarkable differences in affinity between XIAP-
and cIAP1-BIR3 and the monomeric moiety of 9a (IC50 = 230.0
and 5.0 nM, respectively), are strongly reduced in the presence of
the dimeric compound 9a (IC50 = 25.4 and 5.4 nM, respectively),
confirming the ligand induced formation of an energetically
favorable XIAP-BIR3 dimer (reducing the IC50 of the ternary
complex).
Comparative SAXS analysis of XIAP-BIR2BIR3 shows that the
construct in the presence of the inhibitor adopts a more compact
global conformation, likely induced by 9a simultaneous binding to
both BIR domains. However, ensemble analysis (EOM) of free
XIAP-BIR2BIR3 shows that a majority of the molecules adopt a
compact conformation, suggesting that the two domains are
transiently interacting even in the absence of 9a. Such result is also
supported by a molecular dynamics simulation of XIAP-
BIR2BIR3 showing the conservation of an inter-domain interac-
tion surface similar to that observed for XIAP-BIR3/BIR3/9a
crystallographic dimer (data not shown).
A high resolution model of XIAP-BIR2BIR3/9a complex using
the domain crystal structures that nicely fits SAXS data can be
obtained by slightly relaxing the shape of the XIAP-BIR3/9a
crystallographic dimer. In fact, a small separation of the two
domains and the addition of the missing part of the structure
(Coral model, Fig. 7B) lead to a much improved agreement with
the SAXS data (x decreases from 3.04 to 1.30). In this simulated
model, 9a maintains a right handed helical conformation, but with
a pitch that is intermediate relative to both cIAP1-BIR3 (longer)
and XIAP-BIR3 (shorter) (Fig. 7B). The SAXS experimental
evidence of the presence of a transient interaction between XIAP-
BIR2BIR3, even when 9a is absent, indicates that the inhibitor
may shift a preexisting equilibrium between open and closed
conformations of the two domains toward the closed state. As a
result, the overall affinity of XIAP-BIR2BIR3 for the compound
would reflect both the mutual affinity of the two domains and the
affinity of each domain for one 9a inhibitory head. On these bases,
the design of an optimal divalent Smac-mimetic compound should
take into account: i) the affinity of its heads for both BIR2 and
BIR3 (homo or heterodimeric compounds); and, ii) the charac-
teristics of the linker between the two heads, in particular
considering its length, hydrophobicity and conformational free-
dom. Our structural results demonstrate that the 9a linker is well-
suited to favor BIR2/BIR3 native mutual interactions in the
ternary complex: both linker length (comparable with that of one
active head) and conformational degrees of freedom allow 9a to
adopt the observed right handed helical conformation with the two
active heads mutually antiparallel. Moreover, the 9a linker
hydrophobicity warrants an overall compact structure of the free
ligand in solution (to minimize its hydrophobic surface), but with
significant solvent exposure of the two active heads (antiparallel
arrangement), as observed in molecular dynamics simulations of
free 9a in solution (Fig. S2).
Figure 7. Scattering patterns and high resolution model of XIAP-BIR2BIR3 in presence of 9a. A) Experimental data with associated error
bars is reported in black; green line: fit using Bunch and fixed domains with x= 3.04; red line: fit using Coral and mobile domains with distant
restraints between the two heads of 9a (x= 1.30). B) Coral model: XIAP-BIR2BIR3 is represented in white/orange surface for BIR2BIR3/missing parts
build by BUNCH, respectively. 9a is in blue stick and its conformation in XIAP- (shorter helical pitch) and cIAP1-BIR2BIR3 (longer helical pitch) crystal
structures are in green/purple, respectively. The dimer that fit best SAXS data has somehow an intermediate structure with respect to the two
observed crystal structures.
doi:10.1371/journal.pone.0049527.g007
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All results reported here emphasize the importance of structural
dynamics in IAPs interactions with inhibitors and provide new
hints for the development of divalent lead compounds able to bind
preferentially XIAP, cIAP1 and cIAP2, thereby introducing
specificity, albeit partial, in their action on different apoptotic
pathways.
Experimental Procedures
Chemistry
The synthesis of lead divalent compound 9a was reported in
details elsewhere [13]. Briefly, amidation of key intermediate A
[24] with a phenyl-substituted propargylamine gave the alkyna-
mide B, subsequently submitted to a click chemistry experimental
protocol with a bifunctional azide reagent. The resulting bis-Boc
protected tail-tail dimer C was finally deprotected in acidic
conditions to provide pure 9a as a bis-trifluoroacetate in an overall
,30% yield from A (Fig. S3).
Cloning, Expression and Purification
The sequence coding for human XIAP-BIR2BIR3 (140–356)
and cIAP1 and cIAP2-BIR3 (245–357) were cloned in pET21(b)
(Novagen) with a C-terminal 6xHis-tag. The plasmids were used to
transform Escherichia coli strain BL21(DE3). The recombinant
proteins were purified using Ni-NTA (His-trap FFcrude, Ge-
Healthcare), followed by gel filtration (Superdex 200, Ge-
Healthcare). The elution buffers composition was 20 mM Tris
pH 7.5, 200 mM NaCl, 10 mM DTT, and 20 mM Tris pH 8.0,
250 mM NaCl, 10 mM DTT for XIAP-BIR2BIR3 and cIAP1-
BIR3, respectively. Finally, XIAP-BIR2BIR3 and cIAP1-BIR3
were concentrated to 10 mg ml21 for crystallization tests using an
Amicon Ultra centrifugal filter (10 kDa cut-off). XIAP-BIR3
domain was cloned, expressed and purified as already described
[11].
Fluorescence Polarization
Fluorescence polarization assays were performed according to
Lu et al. [10], as also described in Cossu et al. ( [16]). Compound
9a was evaluated for its ability to displace the fluorescent probes
(FITC-SMAC for BIR3 and SMAC-1F for BIR2BIR3) [11], [15–
16] from the recombinant proteins. Fluorescence polarization was
measured on an Ultra plate reader (Tecan), at excitation and
emission wavelengths of 485 nm and 530 nm, respectively. All
experiments were performed in black, flat-bottom 96-well
microplates (Greiner bio-one).
Analytical Gel Filtration Assays
In order to check the simultaneous interaction of compound 9a
with the XIAP-BIR2 and BIR3 domains within the same protein
molecule, analytical gel filtration was performed, using the
construct XIAP-BIR2BIR3 (35 mM) alone or in the presence of
the Smac-mimetic compound (1 mM). In solution, compound 9a
ability to bind to two distinct BIR3 domains from cIAP1 or XIAP
was also evaluated, using a protein concentration of 33 mM with
an equal molar or an excess (1 mM) of 9a. Analytical gel filtration
experiments were performed on a Superdex 200 column (GE
Healthcare) attached to an AKTA Purifier-10 system in Tris-HCl,
(pH 7.5, 20 mM), NaCl (200 mM) and DTT (10 mM). Low
molecular weight standards from Amersham-Biosciences were
used to calibrate the column.
Cellular Cytotoxicity and in vitro-profiling
The MDA-MB-231, HL60 and PC-3 cell lines were obtained
from Interlab Cell Line Collection (ICLC, Genova, Italy). All the
cell lines were cultured at density of 16105 cells per ml in RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS)
and at 37uC and 5% CO2 in fully humidified atmosphere. The
effect of 9a on cell growth was evaluated by means of colorimetric
assay for the quantification of cell proliferation and viability based
on the cleavage of the WST-8 tetrazolium salt by mitochondrial
dehydrogenases in viable cells (Promokine, Germany). The IC50,
the concentration of compound capable of inhibiting the cell
growth by 50%, was calculated using GraphPad Prism 4 software
(see [14]).
Caspase Activation and cIAP Degradation Cell-based
Assays
To test the capability of the inhibitor to induce caspase
activation and apoptosis, MDA-MB-231 cells were left untreated
or treated with 100 nM of 9a, harvested, after 30 minutes and
after 6 hours, and lysed. Proteins were revealed by Western blot
using rabbit polyclonal antibodies specific for cleaved Parp,
cleaved caspase-8, cleaved caspase-9 and cleaved caspase-3 (Cell
Signaling), XIAP (BD Biosciences), cIAP1 and cIAP2 (R&DSys-
tems), and mouse monoclonal anti-bactin (Sigma) as control.
Crystallization and Crystallographic Data Reduction
Sitting drop crystallization experiments were prepared using an
Oryx-8 crystallization robot (Douglas Instruments, East Garston,
UK), from a 2:1 mixture of the protein stock solution (XIAP-BIR3
or cIAP1-BIR3) with 1 mM 9a solution, and the precipitant
solution, to a final drop volume of 0.3 ml for the initial screenings,
and of 0.5 ml for the optimization trials. The screening solutions
used for the experiments were those of Crystal Screens I & II and
Index from Hampton Research (Aliso Viejo, CA, USA). After 1
day of vapour diffusion at 20uC, several irregular-aggregated
crystals were obtained for both the proteins in complex with 9a.
After optimization trials, some single and prismatic crystals of the
complex cIAP1-BIR3/9a were observed in 6% PEG 3350, 0.1 M
BisTRIS pH 5.2, and 0.2 M magnesium chloride. XIAP-BIR3 in
complex with 9a crystallized in 30% PEG400, 0.2 M sodium
citrate, and TRIS pH 7.5. The crystals obtained were soaked in a
cryoprotectant solution containing 25% glycerol and flash-cooled
in liquid nitrogen. The cIAP1-BIR3/9a crystals diffracted to a
maximum resolution of 2.6 A˚ using synchrotron radiation on
beam-line ID29, and the XIAP-BIR3/9a crystals to 3.3 A˚ on
beam-line ID23-1, at the European Synchrotron Radiation
Facility (ESRF-Grenoble, France). The diffraction data were
processed with MOSFLM [25], and intensities were merged using
SCALA [26].
Structure Determination and Refinement
The cIAP1-BIR3/9a crystal belongs to the monoclinic C2 space
group, with unit cell parameters a = 79.1, b = 81.3, c = 96.9 A˚;
b= 95.7u, with 4 molecules in the asymmetric unit (VM = 2.8 A˚
3
Da21, 55% solvent content [27]). The XIAP-BIR3/9a crystals
belong to the orthorhombic P212121 space group, with unit cell
parameters a = 77.7 A˚, b = 108.4 A˚, c = 225.3 A˚, with 10 protein
molecules in the asymmetric unit (VM = 3.3 A˚
3 Da21, 63% solvent
content [27]). The crystal structures of cIAP1-BIR3 and XIAP-
BIR3 in complex with 9a were solved by molecular replacement
(‘molrep’ program [28]), using the structure of the BIR3 domain in
the cIAP1-BIR3/Smac037 (PDB code 3MUP [15]) and in the
XIAP-BIR3/Smac005 (PDB code 2CLX [11]) as search models,
respectively. The 4 independent molecules (A–D) of cIAP1-BIR3/
9a, and the 10 molecules (A–J) of XIAP-BIR3/9a, were subjected
to rigid-body refinement, and subsequently refined using RE-
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FMAC5 [29] and BUSTER [30]. A random set comprising 5% of
the data was omitted from refinement for R-free calculation.
Manual rebuilding [31] and additional refinement [32] were
subsequently performed. Inspection of difference Fourier maps at
this stage showed strong residual density, located between the a3
helix and the main b-sheet, compatible with one of the two Smac-
mimetic heads of the inhibitor for each molecule in the
asymmetric unit, which were accordingly model-built. The density
corresponding to the linker region between the two heads of 9a
became evident after a few cycles of refinement, allowing prompt
model-building of its molecular structure.
In the refined cIAP-BIR3/9a model, the first 12 N-terminal
residues (241–253) and the last 2 C-terminal residues are
disordered. In the XIAP-BIR3/9a model the N-terminal residues
248–253 were model built, but amino acids 241–247 and the last
five C-terminal residues are disordered. Data collection and
refinement statistics are summarized in Table 2. The stereochem-
ical quality of the models was checked using the program Procheck
[33] and is summarized in the Table 2. Atomic coordinates and
structure factors for cIAP1-BIR3/9a and XIAP-BIR3/9a com-
plexes have been deposited with the Protein Data Bank [34] with
accession code 4EB9 and 4EC4 respectively.
Small Angle X-Ray Scattering
X-ray scattering data were collected at the beamline SWING of
Synchrotron SOLEIL (Gif-sur-Yvette, France). All measurements
were performed at 10uC. The data were recorded using a CCD-
based detector (AVIEX) with a sample-detector distance of
2.07 m, covering the range of momentum transfer
0.010,q,0.45 A˚21 (q = 4p sinh/l, where 2h is the scattering
angle and l= 1.033 A˚ the wavelength of the X-rays). XIAP-
BIR2BIR3 with and without 9a was studied in Tris-HCl buffer
20 mM pH 7.5, NaCl 200 mM and 10 mM DTT at protein
concentrations between 1 and 7 mg/ml. Solutions were continu-
ously circulated during data recording through the 1.5 mm
diameter quartz capillary contained in an evacuated vessel using
the automatic sample changer (Agilent) at a flow-rate ensuring an
irradiation time of ca one second. Under these conditions, no
radiation damage could be detected in preliminary tests.
Measurements were also performed using the SE-HPLC instru-
ment (Agilent) online with the SAXS measuring cell, a unique
feature of the SWING beamline [35]. Briefly, 20 ml of a 7 mg
ml21 sample solution were loaded onto the column. Scattering of
the elution buffer before void volume was recorded and used as
buffer scattering to be further subtracted from all protein patterns.
Two-second successive frames were recorded since the elution flow
ensured that no protein was irradiated for more than 0.4 s.
Data were averaged after normalization to the intensity of the
transmitted beam before buffer subtraction using the program
package PRIMUS [36]. The forward scattering I(0) and the radius
of gyration (Rg) were evaluated using the Guinier approximation
[37]. Frames recorded using the SE-HPLC over the monomer
peak were analyzed individually before averaging the appropriate
subset of frames that yield identical Rg and I(0)/c values. The
corresponding concentration was determined using the UV
absorbance detector from the HPLC system and the value of the
protein absorbance at 280 nm e2801% = 20.85. The resulting curve
was spliced with that of the most concentrated sample after scaling
to protein concentration to yield a complete scattering pattern.
The distance distribution function p(r) was determined using the
indirect Fourier transform method as implemented in the program
GNOM [38]. The molecular masses of the solutes were evaluated
by comparison of the forward scattering with that of water
recorded in the same capillary using the value of 0.001647 cm21
for the theoretical scattering intensity of water at 10uC.
Low resolution shapes were determined using the program
Dammif which describes the protein as a compact assembly of
identical dummy atoms [17]. Ten models were calculated and
superimposed using the Damaver suite of routines [39]. They were
compared using the Normalized Spatial Discrepancy (NSD) [40],
the smaller the NSD value the higher the similarity between
models.
The program EOM (version 1.3) describes a flexible molecule in
solution, using an ensemble of typically 50 conformations
extracted from a very large (10,000) pool of conformations [19].
The conformer pool is constructed by connecting domains treated
as rigid bodies by self-avoiding linkers, where the dihedral angles
of the linkers in the Ca–Ca space are selected randomly but biased
to comply with the quasi-Ramachandran plot [41] and the model
generated is free from steric clashes. A genetic algorithm
progressively refines the composition of the ensemble so that the
average scattering pattern of the molecular conformations within
the ensemble fits the experimental data within error bars. The
process was repeated 200 times and the distribution of the radius
of gyration and the maximum diameter were calculated and
compared with those derived from the entire starting pool. This
comparison yields some global features of the conformational
space explored by the molecule as probed by SAXS.
Models of both XIAP-BIR2BIR3 with and without the inhibitor
were obtained using the program Bunch which moves domains as
rigid bodies while describing the missing parts of the molecule (N
and C extremities together with the intervening linker) as chains of
dummy residues (DR) so as to fit the experimental scattering
pattern [18]. Models of the conformation in solution of XIAP-
BIR2BIR3 with 9a were obtained using the program Coral [20]
starting from the high-resolution model of BIR2-BIR3 complexed
with 9a. Here, Coral was used exactly as the program Bunch but
allowed us to impose a 5 A˚ distance restraint between two atoms of
the inhibitor on each side of a broken methylbenzene bond in the
9a central benzene. The core domains complexed with the
corresponding inhibitor moiety were considered as rigid bodies
while missing parts at both N- and C-ends (23 and 8 residue long
respectively) and the central linker (29 residue long) were modeled
as dummy residues (DRs) centered at Ca positions. The DR
chains in resulting models were substituted with a polypeptide
backbone and side-chains were added using the program
SABBAC [42]. The connectivity of the split 9a molecule was
restored using rotational degrees of freedom around single bonds.
Finally the scattering pattern of the model was recalculated using
Crysol [43].
Supporting Information
Figure S1 Five models of Apo XIAP-BIR2BIR3 obtained
by the program Bunch. All models are superimposed over
BIR2 domain (dark grey) in the center of the figure. The spheres
correspond to the dummy residues used by Bunch to represent the
missing parts (N- and C-terminal ends and the central linker).
BIR3 domains are seen in very different orientations and positions
but relatively close to BIR2 (13 A˚ to 19 A˚ between closest Ca
atoms).
(DOCX)
Figure S2 Stable conformation of the free 9a in water.
Briefly, we run a molecular dynamics simulation using the
program Gromacs (www.gromacs.org/) for 10 ns with ’gromacs’
force field (1 fs time step) and periodic boundary conditions (with a
box 33.1641.4637.5 A˚3 filled with 1629 water molecules). Cluster
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conformational analysis shows the achievement of stable confor-
mation (conserved till the end of the simulation) after ,2.5 ns.
Here is shown 9a structure after ,4.3 ns as reference conforma-
tion in the equilibrium structural cluster; the free inhibitor adopt a
compact left-handed helical assembly with antiparallel disposition
of the two active heads; 9a is depicted in an orientation similar to
that reported in Fig. 7 in the main text (drawn with Pymol).
(DOCX)
Figure S3 Schematic procedures for the synthesis of 9a.
(DOCX)
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